Topical alprostadil in the treatment of female sexual arousal disorder: A pilot study

Anita Islam, Jules Mitchel, Raymond Rosen, Nancy Phillips, Charletta Ayers, David Ferguson, James Yeager

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


This study evaluated the efficacy and safety of three doses of topical alprostadil* USP (prostaglandin E1) cream in 8 patients with Female Sexual Arousal Disorder (FSAD). Each patient was administered a single intravaginal dose of placebo followed by escalating intravaginal doses of the active drug at 2-week intervals. Alprostadil’s effectiveness in enhancing subjective and physiological arousal during visual sexual stimulation was supported by patient ratings and physician assessments of vaginal erythema and transudate volume. Photoplethysmography measurement of vaginal pulse amplitude was not able to demonstrate treatment sensitivity in the present study. Adverse events included mild cases of vaginal itching and burning. The data support further investigation of the use of alprostadil for FSAD.

Original languageEnglish (US)
Pages (from-to)531-540
Number of pages10
JournalJournal of Sex and Marital Therapy
Issue number5
StatePublished - Oct 2001

All Science Journal Classification (ASJC) codes

  • Clinical Psychology


Dive into the research topics of 'Topical alprostadil in the treatment of female sexual arousal disorder: A pilot study'. Together they form a unique fingerprint.

Cite this